Having trouble accessing articles? Reset your cache.

Additional MS data for ocrelizumab

Biogen Idec Inc. (NASDAQ:BIIB) and Roche (SIX:ROG; OTCQX:RHHBY) reported additional data from a Phase II

Read the full 158 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE